@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_head { this: np:hasAssertion dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_assertion; np:hasProvenance dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_provenance; np:hasPublicationInfo dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_publicationInfo; a np:Nanopublication . dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_assertion a np:Assertion . dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_provenance a np:Provenance . dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_publicationInfo a np:PublicationInfo . } dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_assertion { miriam-gene:3688 a ncit:C16612 . lld:C0152013 a ncit:C7057 . dgn-gda:DGN6d4d6ef9c86893eb71f9b1d72cfedb4a sio:SIO_000628 miriam-gene:3688, lld:C0152013; a sio:SIO_001121 . } dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_provenance { dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_assertion dcterms:description "[ITGB3 and BCL-2 increased significantly in A549 cells in CAFs group withβ-actin as control; the expression level of BCL-2 also increased in ITGB3 transfected cells with GFP plasmid transfected A549 cells as control; immunohistochemistry staining showed that positive rates of ITGB3, ITGB1 and BCL-2 in normal lung tissues were 0, the positive rates in lung adenocarcinoma were 7.04%, 84.51% and 4.23%, respectively; in the results of immunohistochemistry staining, the expression of Girdin protein in lung adenocarcinoma was homogeneous, however protein expression of ITGB3, ITGB1 and BCL-2 showed different patterns in the same location with significant heterogeneity; majority of ITGB3, ITGB1 or BCL-2 positive tissue showed heterogeneity that expression in trailing edge was higher than that of trailing edge in lung adenocarcinoma tissue, the patients with BCL-2 heterogeneity showed higher lymph node metastasis ratio and lower clinical stage (P<0.05); and the expression of ITGB3 and the clinical characteristics of patients were not significant related (P>0.05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:25066397; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1205436.RAuTgYw_9Gdw-J67mJjSt94AxhfmrM0rK35TIIi71VZ4g130_publicationInfo { this: dcterms:created "2016-05-13T12:50:52+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }